PUBLISHER: Polaris Market Research | PRODUCT CODE: 1504932
PUBLISHER: Polaris Market Research | PRODUCT CODE: 1504932
U.S. Induced Pluripotent Stem Cell (iPSC) Market Share, Size, Trends, Industry Analysis Report, By Derived Cell (Hepatocytes, Fibroblasts, Neural Cells, Amniotic Cells, Cardiomyocytes, Others); By Workflow; By Application; Segment Forecast, 2024 - 2032
The global Induced Pluripotent Stem Cell (iPSC) market size is expected to reach USD 4,355.56 Million by 2032, according to a new study by Polaris Market Research. The report "iPSC Market Share, Size, Trends, Industry Analysis Report, By Derived Cell (Hepatocytes, Fibroblasts, Neural Cells, Amniotic Cells, Cardiomyocytes, Others); By Workflow; By Application; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The growing elderly population, rising cases of chronic diseases, and advancements in research and development are contributing to the increasing growth of the iPSC market. This growth is attracting significant investments from pharmaceutical companies worldwide, who are interested in advanced drug development and testing, and is thereby catering to the overall growth of the iPSC market.
The overall stem cell workflow, although complex, presents a unique opportunity for new entrants in the production of iPSC. Some of the critical and complex processes involved in the production of iPSC include generation, reprogramming, and differentiation into various desired cell types, which require both expertise and resources. However, with the option of commercial iPSC-derived cell purchase or outsourcing programming, new entrants are encouraged to explore this field and contribute to its growth.
With several market entry options available, several trends are observed, such as concentrated efforts on reprogramming and in-house differentiation, purchase of iPSC-derived cell types from off-the-shelf product portfolios, or entering into agreements with third-party purveyors to produce customized models. This trend has spurred a range of possibilities that will feature iPSC-based models for a host of disease models, phenotypic assays, and toxicology testing.
Biopharmaceuticals are drugs that are derived from microbiological sources such as hormones, vaccines, monoclonal antibodies, therapeutic enzymes, blood factors, and so on. These drugs are highly specific and have opened up new avenues in healthcare, such as personalized medicine. This approach involves treating various diseases or conditions using specific biomolecules depending on the patient's physiological, biological, and genetic makeup. As conventional pharmaceuticals have limited applicability and there are few players in the biotechnology industry, the growth of cell culture technology has been fueled.
iPSC Market Report Highlights
In 2023, the global market witnessed significant growth, with cardiomyocytes emerging as the dominant segment. This is because cardiomyocytes, specialized muscle cells in the heart responsible for its contraction and pumping action, have gained significant attention due to their potential for therapeutic applications.
The regenerative medicine industry is projected to experience a substantial growth rate in the upcoming years. Regenerative medicine involves therapeutic techniques that target the repair, replacement, or regeneration of tissues or organs in order to restore normal function in individuals who are suffering from injury or disease.
The North American region dominated the global market, owing to its extensive research and innovation in the field of biomedical science.
The global key market players include Astellas Pharma Inc., Axol Bioscience Ltd., Cynata Therapeutics Limited, Fate Therapeutics, FUJIFILM Holdings Corporation (Cellular Dynamics), Ncardia, REPROCELL Inc., Takara Bio Inc., Thermo Fisher Scientific Inc., ViaCyte, Inc, etc.
Polaris Market Research has segmented the iPSC market report based on derived cell, workflow, application, and region:
iPSC, Derived Cell Outlook (Revenue - USD Million, 2019 - 2032)
- Hepatocytes
- Fibroblasts
- Neural Cells
- Excitatory Neurons
- Inhibitory Neurons
- Amniotic Cells
- Cardiomyocytes
- Others
iPSC, Workflow Outlook (Revenue - USD Million, 2019 - 2032)
- Reprogramming
- Cell Culture
- Cell Characterization / Analysis
- Engineering
- Others
iPSC, Application Outlook (Revenue - USD Million, 2019 - 2032)
- Manufacturing
- Academic Research
- Drug Development & Discovery
- Toxicity Screening
- Regenerative Medicine
iPSC, Regional Outlook (Revenue - USD Million, 2019 - 2032)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Austria
- Netherlands
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Malaysia
- Australia
- Rest of APAC
- Latin America
- Argentina
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
- Rest of MEA
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. U.S. Induced Pluripotent Stem Cell (iPSC) Market Insights
- 4.1. U.S. Induced Pluripotent Stem Cell (iPSC) Market - Industry Snapshot
- 4.2. U.S. Induced Pluripotent Stem Cell (iPSC) Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Advancements in regenerative medicine drives the U.S. iPSC market
- 4.2.1.2. Rising prevalence of chronic diseases drive the U.S. iPSC market growth
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Stringent regulatory framework affects the U.S. iPSC market growth
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTLE Analysis
- 4.5. U.S. Induced Pluripotent Stem Cell (iPSC) Industry trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. U.S. Induced Pluripotent Stem Cell (iPSC) Market, by Derived Cell
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. U.S. Induced Pluripotent Stem Cell (iPSC), by Derived Cell, 2019-2032 (USD Million)
- 5.3. Hepatocytes
- 5.3.1. U.S. Induced Pluripotent Stem Cell (iPSC) Market, by Hepatocytes, 2019-2032 (USD Million)
- 5.4. Fibroblasts
- 5.4.1. U.S. Induced Pluripotent Stem Cell (iPSC) Market, by Fibroblasts, 2019-2032 (USD Million)
- 5.5. Neural Cells
- 5.5.1. U.S. Induced Pluripotent Stem Cell (iPSC) Market, by Neural Cells, 2019-2032 (USD Million)
- 5.5.2. Excitatory Neurons
- 5.5.2.1. U.S. Induced Pluripotent Stem Cell (iPSC) Market, by Excitatory Neurons, 2019-2032 (USD Million)
- 5.5.3. Inhibitory Neurons
- 5.5.3.1. U.S. Induced Pluripotent Stem Cell (iPSC) Market, by Inhibitory Neurons, 2019-2032 (USD Million)
- 5.6. Amniotic Cells
- 5.6.1. U.S. Induced Pluripotent Stem Cell (iPSC) Market, by Amniotic Cells, 2019-2032 (USD Million)
- 5.7. Cardiomyocytes
- 5.7.1. U.S. Induced Pluripotent Stem Cell (iPSC) Market, by Cardiomyocytes, 2019-2032 (USD Million)
- 5.8. Others
- 5.8.1. U.S. Induced Pluripotent Stem Cell (iPSC) Market, by Others, 2019-2032 (USD Million)
6. U.S. Induced Pluripotent Stem Cell (iPSC) Market, by Application
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. U.S. Induced Pluripotent Stem Cell (iPSC) Market, by Application, 2019-2032 (USD Million)
- 6.3. Manufacturing
- 6.3.1. U.S. Induced Pluripotent Stem Cell (iPSC) Market, by Manufacturing, 2019-2032 (USD Million)
- 6.4. Academic Research
- 6.4.1. U.S. Induced Pluripotent Stem Cell (iPSC) Market, by Academic Research, 2019-2032 (USD Million)
- 6.5. Drug Development & Discovery
- 6.5.1. U.S. Induced Pluripotent Stem Cell (iPSC) Market, by Drug Development & Discovery, 2019-2032 (USD Million)
- 6.6. Toxicity Screening
- 6.6.1. U.S. Induced Pluripotent Stem Cell (iPSC) Market, by Toxicity Screening, 2019-2032 (USD Million)
- 6.7. Regenerative Medicine
- 6.7.1. U.S. Induced Pluripotent Stem Cell (iPSC) Market, by Regenerative Medicine, 2019-2032 (USD Million)
7. U.S. Induced Pluripotent Stem Cell (iPSC) Market, by Workflow
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. U.S. Induced Pluripotent Stem Cell (iPSC) Market, by Workflow, 2019-2032 (USD Million)
- 7.3. Reprogramming
- 7.3.1. U.S. Induced Pluripotent Stem Cell (iPSC) Market, by Reprogramming, 2019-2032 (USD Million)
- 7.4. Cell Culture
- 7.4.1. U.S. Induced Pluripotent Stem Cell (iPSC) Market, by Cell Culture, 2019-2032 (USD Million)
- 7.5. Cell Characterization / Analysis
- 7.5.1. U.S. Induced Pluripotent Stem Cell (iPSC) Market, by Cell Characterization / Analysis, 2019-2032 (USD Million)
- 7.6. Engineering
- 7.6.1. U.S. Induced Pluripotent Stem Cell (iPSC) Market, by Engineering, 2019-2032 (USD Million)
- 7.7. Others
- 7.7.1. U.S. Induced Pluripotent Stem Cell (iPSC) Market, by Others, 2019-2032 (USD Million)
8. Competitive Landscape
- 8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
- 8.2. Partnerships/Collaborations/Agreements/Exhibitions
9. Company Profiles
- 9.1. Applied StemCell
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Derived Cell Benchmarking
- 9.1.4. Recent Development
- 9.2. Astellas Pharma Inc
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Derived Cell Benchmarking
- 9.2.4. Recent Development
- 9.3. Catalent, Inc
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Derived Cell Benchmarking
- 9.3.4. Recent Development
- 9.4. Evotec
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Derived Cell Benchmarking
- 9.4.4. Recent Development
- 9.5. Fate Therapeutics
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Derived Cell Benchmarking
- 9.5.4. Recent Development
- 9.6. FUJIFILM Holdings Corporation (Cellular Dynamics)
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Derived Cell Benchmarking
- 9.6.4. Recent Development
- 9.7. REPROCELL Inc
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Derived Cell Benchmarking
- 9.7.4. Recent Development
- 9.8. Takara Bio Inc
- 9.8.1. Company Overview
- 9.8.2. Financial Performance
- 9.8.3. Derived Cell Benchmarking
- 9.8.4. Recent Development
- 9.9. Thermo Fisher Scientific Inc
- 9.9.1. Company Overview
- 9.9.2. Financial Performance
- 9.9.3. Derived Cell Benchmarking
- 9.9.4. Recent Development
- 9.10. ViaCyte, Inc
- 9.10.1. Company Overview
- 9.10.2. Financial Performance
- 9.10.3. Derived Cell Benchmarking
- 9.10.4. Recent Development
List of Tables
- Table 1 U.S. Induced Pluripotent Stem Cell (iPSC) Market, by Application, 2019-2032 (USD Million)
- Table 2 U.S. Induced Pluripotent Stem Cell (iPSC) Market, by Derived Cell, 2019-2032 (USD Million)
- Table 3 U.S. Induced Pluripotent Stem Cell (iPSC) Market, by Workflow, 2019-2032 (USD Million)
List of Figures
- Figure 1 U.S. Induced Pluripotent Stem Cell (iPSC) Market, 2019-2032 (USD Million)
- Figure 2 Integrated Ecosystem
- Figure 3 Research Methodology: Top-Down & Bottom-Up Approach
- Figure 5 Porter's Five Forces
- Figure 6 Market by Application
- Figure 7 U.S. Induced Pluripotent Stem Cell (iPSC) Market, by Application, 2024-2032 (USD Million)
- Figure 8 Market by Derived Cell
- Figure 9 U.S. Induced Pluripotent Stem Cell (iPSC) Market, by Derived Cell, 2024-2032 (USD Million)
- Figure 10 Market by Workflow
- Figure 11 U.S. Induced Pluripotent Stem Cell (iPSC) Market, by Workflow, 2024-2032 (USD Million)
- Figure 13 Strategic Analysis - U.S. Induced Pluripotent Stem Cell (iPSC) Market
